Selective Targeting of Tumour Necrosis Factor Receptor 1 Induces Stable Protection from Crohn's-Like Ileitis in TNFΔARE Mice.

Authors:
Chakraborty R; Maltz MR; Del Castillo D; Tandel PN; Messih N and 2 more

Journal:
J Crohns Colitis

Publication Year: 2022

DOI:
10.1093/ecco-jcc/jjab222

PMCID:
PMC9282884

PMID:
34893805

View on PubMed View on PMC View Publisher
Journal Information

Full Title: J Crohns Colitis

Abbreviation: J Crohns Colitis

Country: Unknown

Publisher: Unknown

Language: N/A

Publication Details

Subject Category: Gastroenterology

Available in Europe PMC: Yes

Available in PMC: Yes

PDF Available: No

Related Papers from Same Journal
Baseline Expression of Immune Gene Modules in Blood is Associated With Primary Response to Anti-TNF…
Bai BYH; Reppell M; Smaoui N and 11 more (2024) - Transparency Score: 4/6
Discontinuation of Anti-Tumour Necrosis Factor Therapy in Patients with Perianal Fistulizing Crohn'…
Ten Bokkel Huinink S; Thomassen D; Steyerberg EW and 17 more (2024) - Transparency Score: 3/6
Faecal Bacteriome and Metabolome Profiles Associated with Decreased Mucosal Inflammatory Activity U…
Hurych J; Mascellani Bergo A; Lerchova T and 17 more (2024) - Transparency Score: 4/6
Faecal Microbiota Transplantation [FMT] in the Treatment of Chronic Refractory Pouchitis: A Systema…
Zaman S; Akingboye A; Mohamedahmed AYY and 6 more (2024) - Transparency Score: 3/6
Maintenance Risankizumab Sustains Induction Response in Patients with Crohn's Disease in a Randomiz…
Ferrante M; Irving PM; Abreu MT and 16 more (2024) - Transparency Score: 4/6
View All Papers from This Journal
Transparency Score
4/6
66.7% Transparent
Transparency Indicators
Click on green indicators to view evidence text
Core Indicators
Evidence found in paper:

"data availability the normalized gene expression data used as the basis of this study have been posted on an open access public site dryad"

Code Sharing
Evidence found in paper:

"Conflict of Interest The authors disclose no financial conflicts."

Evidence found in paper:

"Funding This work was supported by funding from Pfizer Inc. awarded to D.D.L."

Protocol Registration
Open Access
Paper is freely available to read
Additional Indicators
Replication
Novelty Statement
Assessment Info

Tool: rtransparent

OST Version: N/A

Last Updated: Aug 05, 2025